- Home
- LENZ vs ALEC Comparison
LENZ vs ALEC Comparison
Compare LENZ & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LENZ | ALEC |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.4M | 268.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LENZ | ALEC |
|---|---|---|
| Price | $7.79 | $2.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $44.00 | $4.83 |
| AVG Volume (30 Days) | ★ 734.8K | 437.9K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,088,000.00 | ★ $21,045,000.00 |
| Revenue This Year | $50.42 | $2.03 |
| Revenue Next Year | $197.16 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.25 | $1.01 |
| 52 Week High | $50.19 | $3.40 |
Technical Indicators
Market Signals| Indicator | LENZ | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 42.98 |
| Support Level | N/A | $1.89 |
| Resistance Level | $10.34 | $2.57 |
| Average True Range (ATR) | 0.64 | 0.16 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 28.21 | 24.46 |
Price Performance
Historical ComparisonAbout LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.